Price equation captures the role of drug interactions and collateral effects in the evolution of multidrug resistance
Abstract
Bacterial adaptation to antibiotic combinations depends on the joint inhibitory effects of the two drugs (drug interaction [DI]) and how resistance to one drug impacts resistance to the other (collateral effects [CE]). Here we model these evolutionary dynamics on twodimensional phenotype spaces that leverage scaling relations between the drugresponse surfaces of drugsensitive (ancestral) and drugresistant (mutant) populations. We show that evolved resistance to the component drugs – and in turn, the adaptation of growth rate – is governed by a Price equation whose covariance terms encode geometric features of both the twodrugresponse surface (DI) in ancestral cells and the correlations between resistance levels to those drugs (CE). Within this framework, mean evolutionary trajectories reduce to a type of weighted gradient dynamics, with the drug interaction dictating the shape of the underlying landscape and the collateral effects constraining the motion on those landscapes. We also demonstrate how constraints on available mutational pathways can be incorporated into the framework, adding a third key driver of evolution. Our results clarify the complex relationship between drug interactions and collateral effects in multidrug environments and illustrate how specific dosage combinations can shift the weighting of these two effects, leading to different and temporally explicit selective outcomes.
Introduction
Understanding and predicting evolutionary dynamics is an ongoing challenge across all fields of biology. Microbial populations offer relatively simple model systems for investigating adaptation on multiple length scales, from the molecular to the population level, on timescales ranging from a few generations to decades. Yet even these simplest of systems exhibit rich and often counterintuitive evolutionary dynamics. Despite enormous progress, both theoretical and experimental, predicting evolution remains exceedingly difficult, in part because it is challenging to identify the phenotypes, selective gradients, and environmental factors shaping adaptation. In turn, controlling those dynamics – for example, by judicious manipulation of environmental conditions – is often impossible. These challenges represent open theoretical questions but also underlie practical public health threats – exemplified by the rapid rise of antibiotic resistance (Davies and Davies, 2010; Levy and Marshall, 2004) – where evolutionary dynamics are fundamental to the challenge, and perhaps, to the solution.
In recent years, evolutionbased strategies for impeding drug resistance have gained significant attention. These approaches have identified a number of different factors that could modulate resistance evolution, including spatial heterogeneity (Zhang et al., 2011; Baym et al., 2016a; Greulich et al., 2012; Hermsen et al., 2012; MorenoGamez et al., 2015; Gokhale et al., 2018; De Jong and Wood, 2018; SantosLopez et al., 2019); competitive (Read et al., 2011; Hansen et al., 2017; Hansen et al., 2020), cooperative (Meredith et al., 2015b; Artemova et al., 2015; Sorg et al., 2016; Tan et al., 2012; Karslake et al., 2016; Yurtsev et al., 2016; Hallinen et al., 2020), or metabolic (Adamowicz et al., 2018; Adamowicz et al., 2020) interactions between bacterial cells; synergy with the immune system, especially in the context of adaptive treatment (Gjini and Brito, 2016); epistasis between resistance mutations (Trindade et al., 2009; Borrell et al., 2013; Lukačišinová et al., 2020); plasmid dynamics (Lopatkin et al., 2016; Lopatkin et al., 2017; Cooper et al., 2017); precise tuning of drug doses (Lipsitch and Levin, 1997; Yoshida et al., 2017; Meredith et al., 2015a; Nichol et al., 2015; FuentesHernandez et al., 2015; Coates et al., 2018; Iram et al., 2021); cycling or mixing drugs at the hospital level (Bergstrom et al., 2004; Beardmore et al., 2017); and statistical correlations between resistance profiles for different drugs (Imamovic and Sommer, 2013; Kim et al., 2014; Pál et al., 2015; Barbosa et al., 2017; Rodriguez de Evgrafov et al., 2015; Nichol et al., 2019; Podnecky et al., 2018; Imamovic et al., 2018; Barbosa et al., 2019; Rosenkilde et al., 2019; Apjok et al., 2019; Maltas and Wood, 2019; Maltas et al., 2020; HernandoAmado et al., 2020; Roemhild et al., 2020; Ardell and Kryazhimskiy, 2020).
Drug combinations are a particularly promising approach for slowing resistance (Baym et al., 2016b), but the evolutionary impacts of combination therapy remain difficult to predict, especially in a clinical setting (Podolsky, 2015; Woods and Read, 2015). Antibiotics are said to interact when the combined effect of the drugs is greater than (synergy) or less than (antagonism) expected based on the effects of the drugs alone (Greco et al., 1995). These interactions may be leveraged to improve treatments – for example, by offering enhanced antimicrobial effects at reduced concentrations. But these interactions can also accelerate, reduce, or even reverse the evolution of resistance (Chait et al., 2007; Michel et al., 2008; Hegreness et al., 2008; PenaMiller et al., 2013; Dean et al., 2020), leading to tradeoffs between shortterm inhibitory effects and longterm evolutionary potential (Torella et al., 2010). In addition, resistance to one drug may be associated with modulated resistance to other drugs. This crossresistance (or collateral sensitivity) between drugs in a combination has also been shown to significantly modulate resistance evolution (Barbosa et al., 2018; Rodriguez de Evgrafov et al., 2015; Munck et al., 2014).
Collateral effects (Pál et al., 2015; Roemhild et al., 2020) and drug interactions (Bollenbach et al., 2009; Chevereau et al., 2015; Lukačišin and Bollenbach, 2019; Chevereau et al., 2015), even in isolation, reflect interactions – between genetic loci, between competing evolutionary trajectories, between chemical stressors – that are often poorly understood at a mechanistic or molecular level. Yet adaptation to a drug combination may often reflect both phenomena, with the pleiotropic effects that couple resistance to individual drugs constraining, or constrained by, the interactions that occur when those drugs are used simultaneously. In addition, the underlying genotype space is highdimensional and potentially rugged, rendering the genotypic trajectories prohibitively complex (de Visser and Krug, 2014).
In this work, we attempt to navigate these obstacles by modeling evolutionary dynamics on lowerdimensional phenotype spaces that leverage scaling relations between the drugresponse surfaces of ancestral and mutant populations. Our approach is inspired by the fact that multiobjective evolutionary optimization may occur on surprisingly lowdimensional phenotypic spaces (Shoval et al., 2012; Hart et al., 2015). To develop a similarly coarsegrained picture of multidrug resistance, we associate selectable resistance traits with changes in effective drug concentrations, formalizing the geometric rescaling assumptions originally pioneered in Chait et al., 2007; Hegreness et al., 2008; Michel et al., 2008 and connecting evolutionary dynamics with a simple measurable property of ancestral populations. We show that evolved resistance to the component drugs – and in turn, the adaptation of growth rate – is governed by a Price equation whose covariance terms encode geometric features of both (1) the twodrugresponse surface in ancestral populations (the drug interaction) and (2) the correlations between resistance levels to those drugs (collateral effects). In addition, we show how evolutionary trajectories within this framework reduce to a type of weighted gradient dynamics on the twodrug landscape, with the drug interaction dictating the shape of the underlying landscape and the collateral effects constraining the motion on those landscapes, leading to deviations from a simple gradient descent. We also illustrate two straightforward extensions of the basic framework, allowing us to investigate the effects of both constrained mutational pathways and sequential multidrug treatments. Our results clarify the complex relationship between drug interactions and collateral effects in multidrug environments and illustrate how specific dosage combinations can shift the weighting of these two effects, leading to different selective outcomes even when the available genetic routes to resistance are unchanged.
Results
Our goal is to understand evolutionary dynamics of a cellular population in the presence of two drugs, drug 1 and drug 2. These dynamics reflect a potentially complex interplay between drug interactions and collateral evolutionary tradeoffs, and our aim is to formalize these effects in a simple model. To do so, we assume that the per capita growth rate of the ancestral population is given by a function $G(x,y)$, where $x$ and $y$ are the concentrations of drugs 1 and 2, respectively. We limit our analysis to twodrug combinations, but it could be extended to higherorder drug combinations, though this would require empirical or theoretical estimates for higherdimensional drugresponse surfaces (see, e.g., Wood et al., 2012; Zimmer et al., 2016; Zimmer et al., 2017; Russ and Kishony, 2018; Tekin et al., 2016; Tekin et al., 2017; Tekin et al., 2018). At this stage, we do not specify the functional form of $G(x,y)$, though we assume that this function can be derived from pharmacodynamic or mechanistic considerations (Engelstädter, 2014; Bollenbach et al., 2009; Wood and Cluzel, 2012) or otherwise estimated from experimental data (Greco et al., 1995; Wood et al., 2014). In classical pharmacology models (Loewe, 1953; Greco et al., 1995), the shape of these surfaces – specifically, the convexity of the corresponding contours of constant growth (‘isoboles’) – determines the type of drug interaction, with linear isoboles corresponding to additive drug pairs. In this framework, deviations from linearity indicate synergy (concave up) or antagonism (concave down). While there are multiple conventions for assigning geometric features of the response surface to an interactions type – and there has been considerable debate about the appropriate null model for additive interactions (Greco et al., 1995) – the response surfaces contain complete information about the phenotypic response. The manner in which this response data is mapped to a qualitative interaction type – and therefore used to label the interaction as synergistic, for example – is somewhat subjective, though in what follows we adopt the isobolebased labeling scheme because it is more directly related to the geometry of the response surface than competing models (e.g., Bliss independence; Greco et al., 1995).
Resistance as a continuous trait and rescaling in a simple model
The primary assumption of the model is that the phenotypic response (e.g., growth rate) of drugresistant mutants, which may be present in the initial population or arise through mutation, corresponds to a simple rescaling of the growth rate function $G(x,y)$ for the ancestral population. As we will see, this scheme provides an explicit link between a cell’s level of antibiotic resistance and its fitness in a given multidrug environment. Specifically, we assume that the growth rate (g_{i}) of mutant $i$ is given by
where ${\alpha}_{i}$ and ${\beta}_{i}$ are rescaling parameters that reflect the physiological effects of mutations on the growth rate. In some cases – for example, resistance due to efflux pumps (Wood and Cluzel, 2012) or drug degrading enzymes (Yurtsev et al., 2013) – this effective concentration change corresponds to a physical change in intracellular drug concentration. More generally, though, this hypothesis assumes that resistant cells growing in external drug concentration $x$ behave similarly to wildtype (drugsensitive) cells experiencing a reduced effective concentration $\alpha x$. Similar rescaling arguments were originally proposed in Chait et al., 2007, where they were used to predict correlations between the rate of resistance evolution and the type of drug interaction. These arguments have also been used to describe fitness tradeoffs during adaptation (Das et al., 2020) and to account for more general changes in the doseresponse curves, though in many cases the original twoparameter rescaling was sufficient to describe the growth surface in mutants (Wood et al., 2014).
When only a single drug is used, this rescaling leads to a simple relationship between the characteristic inhibitory concentrations – for example, the halfmaximal inhibitory concentration (IC_{50}) or the minimum inhibitory concentration (MIC) – of the ancestral (sensitive) and mutant (resistant) populations. In what follows, we refer to these reference concentrations as ${K}_{i}^{j}$, where $i$ labels the cell type and, when there is more than one drug, $j$ labels the drug. Conceptually, this means that doseresponse curves for both populations have the same basic shape, with resistance (or sensitivity) in the mutant corresponding only to a shapepreserving rescaling of the drug concentration ($D\to D/{K}_{i}$; Figure 1A). In the presence of two drugs, the doseresponse curves become doseresponse surfaces, and rescaling now corresponds to a shapepreserving rescaling of the contours of constant growth. There are now two scaling parameters, one for each drug, and in general they are not equal. For example, in Figure 1B, the mutant shows increased sensitivity to drug 1 ($\alpha \equiv {K}_{\text{WT}}^{1}/{K}_{\text{Mut}}^{1}>1$) and increased resistance to drug 2 ( $\beta \equiv {K}_{\text{WT}}^{2}/{K}_{\text{Mut}}^{2}<1$), where superscripts label the drug (1 or 2) and subscripts label the cell type (wild type, WT; mutant, Mut).
The power of this rescaling approach is that it directly links growth of the mutant populations to measurable properties of the ancestral population (the twodrugresponse surface) via traits of the mutants (the rescaling parameters). Each mutant is characterized by a pair of scaling parameters, $({\alpha}_{i},{\beta}_{i})$, which one might think of as a type of coarsegrained genotype (Figure 1C). When paired with the ancestral growth surface, these traits fully determine the per capita growth rate of the mutant at any external dosage combination $(x,y)$ via Equation 1. While the scaling parameters are intrinsic properties of each mutant, they contribute to the phenotype (growth) in a contextdependent manner, leading to selection dynamics that depend in predictable ways on the external environment (Figure 1).
We assume a finite set of $M$ subpopulations (mutants), ($i=1,\dots M$), with each subpopulation corresponding to a single pair of scaling parameters. For simplicity, initially we assume each of these mutants is present in the original population at low frequency and neglect mutations that could give rise to new phenotypes, though later we show that it is straightforward to incorporate them into the same framework. We do not specify the mechanisms by which this standing variation is initially generated or maintained; instead, we simply assume that such standing variation exists, and our goal is to predict how selection will act on this variation for different choices of external (true) drug concentrations. As we will see, statistical properties of this variation combine with the local geometry of the response surface to determine the selection dynamics of these traits.
Population dynamics of scaling parameters
The mean resistance trait to drug 1, which in our case is the scaling parameter $\overline{\alpha}(t)\equiv {\sum}_{i=1}^{M}{\alpha}_{i}{f}_{i}(t)$, evolves according to
where ${f}_{i}(t)$ is the population frequency of mutant $i$ at time $t$ in the population. Assuming that each subpopulation grows exponentially at the per capita growth rate ($d{n}_{i}/dt={g}_{i}{n}_{i}$, with n_{i} the abundance of mutant $i$ and g_{i} the per capita growth rate given by Equation 1), the frequency ${f}_{i}(t)$ changes according to
where $\overline{g}={\sum}_{i=1}^{M}{f}_{i}{g}_{i}$ is the (timedependent) mean value of g_{i} across all $M$ subpopulations (mutants). Combining Equations 2 and 3, we have
where $\mathrm{Cov}{(\alpha ,g)}_{\mathit{\bm{x}}}\equiv {\sum}_{i=1}^{M}{\alpha}_{i}{f}_{i}({g}_{i}\overline{g})$ is the covariance between the scaling parameters ${\alpha}_{i}$ and the corresponding mutant growth rates g_{i}. The subscript $\mathit{\bm{x}}$ is a reminder that the growth rates g_{i} and $\overline{g}$ that appear in the covariance sum depend on the external (true) drug concentration $\mathit{\bm{x}}\equiv (x,y)$. An identical derivation leads to an analogous equation for the scaling parameter with respect to drug 2, mean susceptibility to drug 2, $\overline{\beta}$, relative to the original population, and the full dynamics are therefore described by
To complete the model described by Equation 5, one must specify the external (true) concentration of each drug ($\mathit{\bm{x}}$); a finite set of scaling parameter pairs ${\alpha}_{i},{\beta}_{i}$ corresponding to all ‘available’ mutations; and an initial condition $(\overline{\alpha}(0),\overline{\beta}(0))$ for the mean scaling parameters. When combined with the external drug concentrations, the scaling parameters directly determine the effective drug concentrations (${D}_{1}^{\text{eff}},{D}_{2}^{\text{eff}}$) experienced by each mutant according to
We note that drug concentrations can be above or below the MIC contour, with higher concentrations leading to population collapse ($G<0$) and lower concentrations to population growth ($G>0$) in the ancestral (drug sensitive) cells. However selection dynamics remain the same in both cases as selection depends only on differences in growth rates between different subpopulations.
Equation 5 is an example of the wellknown Price equation from evolutionary biology (Price, 1970; Price, 1972; Frank, 1995; Lehtonen et al., 2020), which says that the change in the (population) mean value of a trait is governed by the covariance of traits and fitness. In general, fitness can be difficult to measure and, in some cases, even difficult to define. However, the rescaling assumption of our model replaces fitness with $g$, which can be directly inferred from measurable properties (the twodrugresponse surface) in the ancestral population. In what follows, we will sometimes casually refer to Equation 5 as a ‘model,’ but it is important to note that the Price equation is not, in and of itself, a mathematical model in the traditional sense. Instead, it is a simple mathematical statement describing the statistical relationship between variables, which are themselves defined in some underlying model. In this case, the mathematical model consists of a collection of exponentially growing populations whose per capita growth rates are linked by scaling relationships. Equation 5– the Price equation – does not include additional assumptions, mechanistic or otherwise, but merely captures statistical relationships between the model variables. We will see, however, that these relationships provide conceptual insight into the interplay between collateral effects and drug interactions.
Equation 5 encodes deceptively rich dynamics that depend on both the interaction between drugs and the collateral effects of resistance. First, it is important to note that αs and βs vary together in pairs, and the evolution of these two traits is not independent. As a result, constraints on the joint cooccurrence of ${\alpha}_{i}$ and ${\beta}_{i}$ among the mutant subpopulations can significantly impact the dynamics. These constraints correspond to correlations between resistance levels to different drugs – that is, to crossresistance (when pairs of scaling parameters simultaneously increase resistance to both drugs) or to collateral sensitivity (when one scaling parameter leads to increased resistance and the other to increased sensitivity). In addition, $g$ contains information about the doseresponse surface and, therefore, about the interaction between drugs. The evolution of the scaling parameters is not determined solely by the drug interaction or by the collateral effects, but instead by both – quantified by the covariance between these rescaled trait values and the ancestral doseresponse surface.
As an example, we integrated the model numerically to determine the dynamics of the mean scaling parameters and the mean growth rate for a population exposed to a fixed concentration of two drugs whose growth surface has been fully specified (Figure 2A). The dynamics can be thought of as motion on the twodimensional response surface; if the initial population is dominated by the ancestral cells, the mean scaling parameters are approximately 1, and the trajectory therefore starts near the point representing the true drug concentration (in this case, $({x}_{0},{y}_{0})$), where growth is typically small (Figure 2A). Over time, the mean traits evolve, tracing out a trajectory in the space of scaling parameters (Figure 2B). When the external concentration of drug is specified, these dynamics also correspond to a trajectory through the space of effective drug concentrations, which, in turn, can be linked with an average growth rate through the drugresponse surface (Figure 2B). The model therefore describes both the dynamics of the scaling parameters, which describe how resistance to each drug changes over time (Figure 2C), and the dynamics of growth rate adaptation in the population as a whole (Figure 2D).
Selection dynamics depend on drug interaction and collateral effects
This rescaling model indicates that selection is determined by both the drug interaction and the collateral effects, consistent with previous experimental findings. As a simple example, consider the case of a fixed drug interaction but different qualitative types of collateral effects – that is, different statistical relationships between resistance to drug 1 (via α) and resistance to drug 2 (via β). In Figure 3A, we consider cases where resistance is primarily to drug 2 (black), primarily to drug 1 (cyan), strongly positively correlated (crossresistance, pink), and strongly negatively correlated (collateral sensitivity, green). Using the same drug interaction surface as in Figure 2, we find that a mixture of both drugs leads to significantly different trajectories in the space of scaling parameters (Figure 3B) and, in turn, significantly different rates of growth adaptation. In this example, crossresistance (pink) leads to rapid increases in resistance to both drugs (rapid decreases in scaling parameters, Figure 3C, D) and the fastest growth adaptation (Figure 3E). By contrast, if resistance is limited primarily to one drug (cyan or black), growth adaptation is slowed (Figure 3E) – intuitively, purely horizontal or purely vertical motion in the space of scaling parameters leads to only a modest change in growth because the underlying response surface is relatively flat in those directions, meaning that the rescaled concentration, in each case, lies near the original contour (Figure 3). As a result of the contour shapes (drug interaction), resistance to both drugs can develop at approximately the same rate (for example), even when collateral structure suggests resistance to one drug will dominate (e.g., cyan case in Figure 3). We note that the dynamics will depend on the (true) external drug concentrations $({x}_{0},{y}_{0})$, even if the rescaling parameters remain identical, because a given rescaling transformation will lead to different effective drug concentrations, and therefore different growth rates, for different values of $({x}_{0},{y}_{0})$.
When both collateral effects and drug interactions vary, the dynamics can be considerably more complex, and the dominant driver of adaptation can be drug interaction, collateral effects, or a combination of both. Previous studies support this picture as adaptation has been observed to be driven primarily by drug interactions (Chait et al., 2007; Michel et al., 2008; Hegreness et al., 2008), primarily by collateral effects (Munck et al., 2014; Barbosa et al., 2018), or by combinations of both (Baym et al., 2016b; Barbosa et al., 2018; Dean et al., 2020). Figure 4 shows schematic examples of growth rate adaptation for different types of collateral effects (rows, ranging from crossresistance [top] to collateral sensitivity [bottom]) and drug interactions (columns, ranging from synergy [left] to antagonism [right]). The growth adaptation may also depend sensitively on the external environment – that is, on the true external drug concentration (blue, cyan, and red). In the absence of both drug interactions (linear isoboles) and collateral effects (uncorrelated scaling parameters), adaptation is slower when the drugs are used in combination than when they are used alone, consistent with the fact that adaptation to multiple stressors is expected to take longer than adaptation to each stressor alone (Figure 4; middle row, middle column). As in Figure 3, modulating collateral effects with drug interaction fixed can have dramatic impacts on adaptation (Figure 4, columns). On the other hand, modulating the drug interaction in the absence of collateral effects will also significantly impact adaptation, with synergistic interactions leading to accelerated adaptation relative to other types of drug interaction (Figure 4, middle row; compare green curves across row). Similar interactiondriven adaptation has been observed in multiple bacterial species (Chait et al., 2007; Michel et al., 2008; Hegreness et al., 2008; Dean et al., 2020).
Selection as weighted gradient dynamics on the ancestral response surface
To gain intuition about the dynamics in the presence of both collateral effects and drug interactions, we consider an approximately monomorphic population where scaling parameters are initially narrowly distributed around their mean values. In this case, we can Taylor expand the function ${g}_{i}=G({\alpha}_{i}{x}_{0},{\beta}_{i}{y}_{0})$ (corresponding to the growth of mutant $i$) around the mean values $\overline{\alpha}$, $\overline{\beta}$, leading to
where we have neglected terms quadratic and higher. In this regime, g_{i} is a linear function of the scaling parameters, and the covariances can therefore be written as
where ${\sigma}_{uv}=\overline{uv}\overline{u}\overline{v}$ and we have used the fact that $\overline{g}\equiv {\sum}_{i}{f}_{i}G({\alpha}_{i}{x}_{0},{\beta}_{i}{x}_{0})=G(\overline{\alpha}{x}_{0},\overline{\beta}{y}_{0})$ to first order. This is a type of weakselection approximation: the trait that is evolving may have a very strong effect on fitness, but if there is only minor variation in such trait in the population, there will only be minor differences in fitness. Equation 5 for the rate of change in mean traits therefore reduces to
where $\overline{\mathit{\bm{\alpha}}}$ is a vector of mean scaling factors with components $\overline{\alpha}$ and $\overline{\beta}$, $\mathbf{\mathbf{\Sigma}}$ is a covariancelike matrix given by
and $\nabla G$ is a weighted gradient of the function $G(x,y)$ evaluated at the mean scaling parameters,
Equation 9 provides an accurate description of the full dynamics across a wide range of conditions (Figure 4—figure supplement 1) and has a surprisingly simple interpretation. Adaptation dynamics are driven by a type of weighted gradient dynamics on the response surface, with the weighting determined by the correlation coefficients describing resistance levels to the two drugs. In the absence of collateral effects – for example, when $\mathbf{\mathbf{\Sigma}}$ is proportional to the identity matrix – the scaling parameters trace out trajectories of steepest ascent on the twodrugresponse surface. That is, in the absence of constraints on the available scaling parameters, adaptation follows the gradient of the response surface to rapidly achieve increased fitness, and because the response surface defines the type of drug interaction, that interaction governs the rate of adaptation. On the other hand, collateral effects introduce offdiagonal elements of $\mathbf{\mathbf{\Sigma}}$, biasing trajectories away from pure gradient dynamics to account for the constraints of collateral evolution.
Model predicts experimentally observed adaptation of growth and resistance
Our model makes testable predictions for adaptation dynamics of both the population growth rate and the populationaveraged resistance levels to each drug (i.e., the mean scaling parameters) for a given drugresponse surface, a given set of available mutants, and a specific combination of (external) drug dosages. To compare predictions of the model with experiment, we solved Equation 5 for the 11 different dosage combinations of tigecycline (TGC) and ciprofloxacin (CIP) used to select drugresistance mutants in Dean et al., 2020. We assumed that the initial population was dominated by ancestral cells ($\alpha =\beta =1$) but also included a subpopulation of resistant mutants whose scaling parameters were uniformly sampled from those measured across multiple days of the evolution (see Materials and methods). The model predicts different trajectories for different external doses (selective regimes: red to blue, Figure 5, top panel), leading to dramatically different changes in resistance (IC_{50}) and growth rate adaptation (Figure 5, bottom panels), similar to those observed in experiment. Specifically, the model predicts (and experiments confirm) a dramatic decrease in CIP resistance as TGC concentration is increased along a contour of constant growth. As TGC eclipses acritical concentration of approximately 0.025 g/mL, selection for both CIP resistance and increased growth is eliminated. We note that comparisons between the model and experiment involve no adjustable parameters, and while the model captures the qualitative trends, it slightly but systematically underestimates the growth across TGC concentrations – perhaps suggesting additional evolutionary dynamics not captured by the model. Intuitively, the experimental results can be explained by the strongly antagonistic interaction between the two drugs, which reverses the selection for resistance to CIP at sufficiently high TGC concentrations (compare CIP resistance at TGC = 0 and TGC = 0.04 g/mL, which both involve CIP ≈ 0.2 g/mL; similar results have been seen in other species and for other drug combinations; Chait et al., 2007). We also compared model predictions with experimental adaptation to two additional drug pairs (Figure 5—figure supplements 1 and 2) and again found that the model captures the qualitative features of both resistance changes to the component drugs and growth adaptation.
Effects of mutations
While we have focused on selection dynamics, the model can be extended to include mutation events linking different phenotypes (i.e., linking different pairs of scaling parameters). These mutational pathways may be necessary to capture certain evolutionary features – for example, historical contingencies between sequentially acquired mutations (Barbosa et al., 2017; Card et al., 2019; Das et al., 2020). To incorporate mutational structure and processes, we modify the equation for each subpopulation ${n}_{i}$ to
where μ is the mutation rate and ${m}_{ji}$ is the probability that strain $j$ mutates to strain $i$, given that there is a mutation in strain $j$. We will refer to the matrix formed by the parameters ${m}_{ji}$ as the mutation matrix as it contains information about allowed mutational trajectories linking different phenotypes (Day and Gandon, 2006). The Price equation for the mean traits (the mean scaling parameters) now becomes
where ${\overline{\alpha}}_{m}$ and ${\overline{\beta}}_{m}$ are the mean trait values in all mutants that arise, and are given by
When the mutation matrix has a particularly simple structure, the effects of mutation will be similar to those of selection. For example, when mutations occur with uniform probability between the ancestral strain and each mutant, the evolutionary dynamics are qualitatively similar to those in the absence of mutation (Figure 6—figure supplement 1, compare to Figure 4). On the other hand, certain mutational structures can lead to new behavior. As an example, we consider a toy model consisting of four phenotypes defined by the level of resistance (sensitive, S, or resistant, R) to one of two drugs. The phenotypes are designated SS $(\alpha =1,\beta =1)$, RS $(\alpha =1/5,\beta =1)$, SR $(\alpha =1,\beta =1/5)$, or RR $(\alpha =1/5,\beta =1/5)$. Note that these phenotypes do not assume, a priori, any particular relationships between the underlying genotypes. For example, each phenotype could correspond to a single mutation – in which case the RR phenotype would be said to exhibit strong crossresistance – or alternatively, the phenotypes could correspond to single drug mutants (SR and RS) and double mutants (RR), which implies a particular sequence in which the mutations can be acquired. These two situations would lead to significant differences in the expected structure of the mutational matrix and, as we will see, in the evolutionary dynamics.
For simplicity, we consider two different mutational structures: one corresponding to direct and uniform pathways between the ancestor (SS) and all mutant phenotypes (SR, RS, and RR), and the second corresponding to sequential pathways from ancestor to single mutants (SR, RS) and then from single mutants to double mutants (Figure 6). To illustrate the impact of mutational structure, we consider two drugs that interact antagonistically and choose the external drug concentrations such that ${D}_{1}>{D}_{2}$ (Figure 6C). While both mutational structures lead eventually to a population of doubleresistant phenotypes (RR), the sequential pathway leads to slower adaptation of growth as the population evolves first toward the most fit single mutant (in this case, RS because the drug combination contains a higher concentration of drug 1) before eventually arriving at RR (Figure 6C–E). The specific trajectory will of course depend on both the drug interaction (the shape of the growth contours) and the specific dosage combination (see Figure 6—figure supplement 2).
There are other types of mutational constraints that can be implemented in the formalism, including explicit functional dependencies between different antibiotic resistance phenotypes. As an example, we assumed a distancebased mutation matrix where the mutation probability between different strains depends on the Euclidean distance between their scaling parameter pairs (${\alpha}_{i},{\beta}_{i}$) according to ${m}_{ji}\sim {e}^{{d}_{ji}}$, where ${d}_{ji}=\sqrt{{({\alpha}_{i}{\alpha}_{j})}^{2}+{({\beta}_{i}{\beta}_{j})}^{2}}$. Intuitively, this structure means that mutations are more likely between strains with similar rescaling parameters (and therefore similar levels of resistance to the component drugs). As expected, this constrained mutational structure leads to slower growth rate adaptation than a model with a simple uniform mutation model (Figure 6—figure supplement 3). These effects are further compounded by statistical properties of the collateral structures (e.g., positive or negative correlations between the possible αs and βs; Figure 3), the specific (stochastic) realization of those scaling parameters (Figure 6—figure supplement 4), and the precise shape of twodrug growth surface. Note, however, that these dynamics depend fundamentally on the global mutation rate μ, which modulates the relative balance between selection and mutation in a given environment.
Evolutionary dynamics under temporal sequences of drug combinations
Evolutionary dynamics in the presence of multiple drugs can be extremely complex. While past work has focused primarily on the use of either temporal sequences or (simultaneous) combinations of antibiotics, more complex scenarios are possible, in principle, but difficult to analyze even in theoretical models. The simplicity of the Price equation framework allows us to investigate evolutionary dynamics in response to a more complex scenario: temporal sequences of antibiotic combinations. As proof of principle, we numerically studied timedependent therapies consisting of two sequential regimes (treatment A and treatment B; Figure 7) characterized by different dosage combinations of tigecycline (drug 1) and ciprofloxacin (drug 2) (the growth surface was measured in Dean et al., 2020). The two dosage combinations were chosen to lie along a contour of constant growth (Figure 7A), meaning that the net inhibitory effects of A and B are the same when applied to ancestral cells. Using experimental estimates for $\alpha ,\beta $ (Figure 3—figure supplement 1C), we find that both the resistance levels to the two drugs and the growth rate increase during treatment, as one might expect. However, the dynamics of these changes depend on both the relative duration of each treatment and total treatment length (Figure 7—figure supplements 1 and 2). For example, consider a treatment of total length $T$ consisting of an initial period of treatment A followed by a final period of treatment B. If we vary the relative length of the two epochs while keeping the total treatment length fixed, we find that the resistance to each drug and the growth rate increase monotonically as the fraction of time in B increases (Figure 7H–J). This is a consequence of the interplay between the distribution of available mutants and the shape of the growth surface under these particular two drugs; the mutants tend to feature higher levels of resistance to drug 2 than drug 1, yet the benefits of this resistance – that is, the increase in growth rate due to rescaling the concentration of drug 2 – are favored much more so under condition B than condition A (where rescaling tends to produce effective drug concentrations that lie near the original growth contour). It is notable, however, that effects (both resistance levels and final growth) change nonlinearly as the fraction of time in B is increased – that is, even in this simple model, the effects of a twoepoch (A then B) treatment cannot be inferred as a simple linear interpolation between the effects of Aonly and Bonly treatments.
Discussion
Antibiotic resistance is a growing threat to modern medicine and public health. Multidrug therapies are a promising approach to both increase efficacy of treatment and prevent evolution of resistance, but the two effects can be coupled in counterintuitive ways through the drug interactions and collateral effects linking the component drugs. Our results provide a unified framework for incorporating both drug interactions and collateral effects to predict phenotypic adaptation on coarsegrained fitness landscapes that are measurable features of the ancestral population (Table 1). Special cases of the model reproduce previous experimental results that appear, on the surface, to be contradictory; indeed, adaptation can be driven primarily by drug interactions, primarily by collateral effects, or by a combination of both, and the balance of these effects can be shifted using tunable properties of the system (i.e., the ratio of drug dosages). Our model was inspired by rescaling arguments that were originally introduced in Chait et al., 2007 and have since been shown to capture phenotypic features of doseresponse surfaces or adaptation in multiple bacterial species (Michel et al., 2008; Hegreness et al., 2008; Torella et al., 2010; Wood and Cluzel, 2012; Wood et al., 2014; Dean et al., 2020; Das et al., 2020). Our results complement these studies by showing how similar rescaling assumptions, when formalized in a population dynamics model, lead to testable predictions for the dynamics of both growth adaptation and phenotype (resistance) evolution. Importantly, the model also has a simple intuitive explanation, with evolutionary trajectories driven by weighted gradient dynamics on twodimensional landscapes, where the local geometry of the landscape reflects the drug interaction and collateral effects constrain the direction of motion. We have also illustrated how de novo mutation can be integrated in the same framework, provided the mutational structure among a pool of possible phenotypes is known or if specific assumptions are made regarding functional links and constraints for shifts between different resistance levels. Mutation at constant rate is indeed a classic version of the complete Price equation. However, more complex mutational effects – including stressdependent modulation of mutation rate (Kohanski et al., 2010; Vasse et al., 2020) – could be included as a more flexible tunable term in Equation 5.
It is important to keep in mind several limitations of our approach. The primary rescaling assumption of the model is that growth of a drugresistant mutant is well approximated by growth of the ancestral strain at a new ‘effective’ drug concentration – one that differs from the true external concentration. This approximation has considerable empirical support (Chait et al., 2007; Wood and Cluzel, 2012; Wood et al., 2014; Das et al., 2020) but is not expected to always hold; indeed, there are examples where mutations lead to more complex nonlinear transformations of the drugresponse surface (Wood et al., 2014; Munck et al., 2014). In addition, it is possible that selection can act on some other feature of the doseresponse curve characterizing singledrug effects – modulating, for example, its steepness (rather than merely its scale). While these effects could in principle be incorporated into our model – for example, by assuming transformations of the ancestral surface, perhaps occurring on a slower timescale, that go beyond simple rescaling – we have not focused on those cases. For simplicity, we have also neglected a number of features that may impact microbial evolution. For example, we have assumed that different subpopulations grow exponentially, neglecting potential interactions including clonal interference (Gerrish and Lenski, 1998), intercellular (Koch et al., 2014; Hansen et al., 2017; Hansen et al., 2020) or intralineage (Ogbunugafor and Eppstein, 2017) competition, and cooperation (Yurtsev et al., 2013; Sorg et al., 2016; Estrela and Brown, 2018; Frost et al., 2018; Hallinen et al., 2020), as well as potential effects of demographic noise and population extinction (Coates et al., 2018). These complexities could also be incorporated in our model, perhaps at the expense of some intuitive interpretations (e.g., weighted gradient dynamics) that currently apply. In addition, we have not explicitly included a fitness cost of resistance (Andersson and Hughes, 2010) – that is, we assume that growth rates of mutants and ancestral cells are identical in the absence of drug. This assumption could be relaxed by including a prefactor to the growth function, ${g}_{i}\to (1{\gamma}_{i}({\alpha}_{i},{\beta}_{i})){g}_{i}$, where ${\gamma}_{i}({\alpha}_{i},{\beta}_{i})$ is the cost of resistance, which in general depends on the scaling parameters (if not, it can be easily incorporated as a constant). While such fitness costs have traditionally been seen as essential for reversing resistance (with, e.g., drugfree ‘holidays’; Dunai et al., 2019), our results underscore the idea that reversing adaptation relies on differential fitness along a multidimensional continuum of environments, not merely binary (drug/no drug) conditions. Our results indicate resistance and bacterial growth can be significantly constrained by optimal tuning of multidrug environments, even in the absence of fitness cost. Finally, our model deals only with heritable resistance and therefore may not capture phenotypic affects associated with, for example, transient resistance (El Meouche and Dunlop, 2018) or cellular hysteresis (Roemhild et al., 2018).
Our goal was to strike a balance between analytical tractability and generality vs. biological realism and system specificity. But we stress that the predictions of this model do not come for free; they depend, for example, on properties of the doseresponse surfaces, the collection of scaling parameters, and the specific mutational structure. In many cases, these features can be determined empirically; in other cases, some or all of these properties may be unknown. The evolutionary predictions of the model will ultimately depend on these inputs, and it is difficult to draw general conclusions (e.g., 'synergistic combinations always accelerate resistance') that apply across all classes of drug combinations, collateral effects, and mutational structures. But we believe the framework is valuable precisely because it generates testable predictions in situations that might otherwise seem intractably complex.
Our approach also has pedagogical value as it connects evolutionary effects of drug combinations and collateral effects with wellestablished concepts in evolutionary biology and population genetics (Price, 1970; Price, 1972; Day and Gandon, 2006). Approximations similar to Equation 9 have been derived previously in quantitative genetics models (Abrams et al., 1993; Taylor, 1996) and other applications of the Price equation (Lehtonen, 2018). While the gradient approximation does not require that the population be monomorphic with rare mutants or a particular form for the phenotype distribution, it does require that the majority of trait values (here scaling parameters) are contained in a regime where $G(x,y)$ is approximately linear; in our case, that linearity arises by Taylor expansion and neglecting higherorder deviations from the population mean. More generally, the direction of evolutionary change in our model is determined by the gradient of the fitness function $\nabla G$ evaluated at the mean trait $(\overline{\alpha},\overline{\beta})$; when the gradient vanishes, this point corresponds to a singular point (Waxman and Gavrilets, 2005) or an evolutionarily singular strategy (Geritz et al., 1998). Whether such point may be reached (convergence stability) and how much variance in trait values can be maintained around such point (whether evolutionarily stable [ESS]) depend on other features, such as higherorder derivatives (Otto and Day, 2011; Eshel et al., 1997; Lehtonen, 2018; Smith, 1982; Parker and Smith, 1990). In the case of drug interactions, the fitness landscape in $(\alpha ,\beta )$ space will typically have a single maximum at (0, 0) corresponding to effective drug concentrations of zero. However, whether that point is reachable in general or within a given time frame will depend on the available mutants preexisting at very low frequencies in the population, or on the speed and biases in the mutational process itself, if such mutants are to be generated de novo during treatment. In principle, the model also allows for longterm coexistence between different strains; in that case, the rescaled effective drug concentrations experienced by both strains would fall along a single contour of constant growth. Hence, while variance in the population growth will necessarily decrease over time, variance in the traits (scaling parameters) themselves can change nonmonotonically.
The framework is sufficiently flexible to integrate different strands of empirical data, and our results underscore the need for quantitative phenotype data tracking resistance to multiple drugs simultaneously, especially when drug combinations are potentially driving selection dynamics. At an epidemiological level, the dominant approach in describing resistance has been to use fixed breakpoints in MIC and track the percentage of isolates with MIC above (drugresistant) or below (drugsensitive) such breakpoint (e.g., ECDC, 2019; Chang et al., 2015). By missing or decoupling patterns of cooccurrence between MICs to different drugs across isolates, this approach remains incomplete for mechanistic predictions. Our framework suggests that going beyond such binary description towards a more continuous and multidimensional phenotype characterization of drug resistance is possible, with applications not just in microbiology but also in the evolutionary epidemiology of drug resistance (Day and Gandon, 2012; Day et al., 2020). In the long run, these advances may yield better and more precise predictions of resistance evolution at multiple scales, and, in turn, optimized treatments that balance shortterm inhibitory effects of a drug cocktail with its inseparable, longerterm evolutionary consequences.
Perhaps most importantly, our approach provides a lowdimensional approximation to the highdimensional dynamics governing the evolution of resistance. In contrast to the classical genotypecentric approaches to resistance, our model uses rescaling arguments to connect measurable traits of resistant cells (scaling parameters) to environmentdependent phenotypes (growth). This rescaling dramatically reduces the complexity of the problem as the twodrugresponse surfaces – and, effectively, the fitness landscape – can be estimated from only singledrug doseresponse curves. Such coarsegrained models can help extract simplifying principles from otherwise intractable complexity (Shoval et al., 2012; Hart et al., 2015). In many ways, the classical Price equation performs a similar function, revealing links between traitfitness covariance and selection that, at a mathematical level, are already embedded in simple models of population growth. In the case of multidrug resistance, this formalism reveals that drug interactions and collateral effects are not independent features of resistance evolution, and neither, alone, can provide a complete picture. Instead, they are coupled through local geometry of the twodrugresponse surface, and we show how specific dosage combinations can shift the weighting of these two effects, providing a framework for systematic optimization of timedependent multidrug therapies.
Materials and methods
Estimating scaling parameters from experimental doseresponse curves
Request a detailed protocolThe scaling parameters for a given mutant can be directly estimated by comparing singledrug doseresponse curves of the mutant and ancestral populations. To do so, we estimate the halfmaximal inhibitory concentration (${K}_{i}$) for each population by fitting the normalized doseresponse curve to a Hilllike function ${g}_{i}(d)={(1+{(d/{K}_{i})}^{h})}^{1}$, with ${g}_{i}(d)$ the relative growth at concentration $d$ and $h$ a Hill coefficient measuring the steepness of the doseresponse curve using nonlinear leastsquares fitting. The scaling parameter for each drug is then estimated as the ratio of the ${K}_{i}$ parameters for the ancestral and mutant populations. For example, an increase in resistance corresponds to an increase in ${K}_{i}$ for the mutant population relative to that of the ancestor, yielding a scaling parameter of less than 1. Estimates for the scaling parameters for the three drug combinations used here are shown in Figure 3—figure supplement 1 (from data in Dean et al., 2020).
While it is straightforward to estimate the scaling parameters for any particular isolate, it is not clear a priori which isolates are present at time 0 of any given evolution experiment. To compare predictions of our model with lab evolution experiments, we first estimated scaling parameters for all isolates collected during lab evolution experiments in each drug pair (Dean et al., 2020). This ensemble includes 50–100 isolates per drug combination and includes isolates collected at different timepoints during the evolution (after days 1, 2, or 3) as well as isolates selected in different dosage combinations Figure 3—figure supplement 1. We then randomly sampled from this ensemble to generate lowlevel standing diversity (on average, approximately 10 distinct pairs of scaling parameters) at time 0 for each simulation of the model, and we repeated this subsampling 100 times to generate an ensemble of evolutionary trajectories for each condition.
The results of the simulation can, in principle, depend on how these scaling parameters are sampled. While the qualitative differences between simulations do not depend heavily on this choice of subsampling in the data used here (Figure 5—figure supplement 3), one can imagine scenarios where details of the subsampling significantly impact the outcome. Similarly, precise comparison with experiment requires accurate estimates for the total evolutionary time and for the initial frequency of all resistant mutants, though for these data the qualitative results do not depend sensitively on these choices (Figure 5—figure supplement 4 and Figure 5—figure supplement 5). We stress that these are not fundamental limitations of the model itself, but instead arise because we do not have a precise measure of the standing variation characterizing these particular experiments. In principle, a more accurate ensemble of scaling parameters could be inferred from cleverly designed fluctuation tests (Luria and Delbrück, 1943) or, ideally, from highthroughput, singlecell phenotypic studies (Baltekin et al., 2017). At a theoretical level, subsampling could also be modulated to simulate the effects of different effective population sizes, with standing diversity expected to be significantly larger for large populations.
Data availability
Data used in this paper was taken from a public repository: Dean, Ziah; Maltas, Jeff; Wood, Kevin (2020), Antibiotic interactions shape shortterm evolution of resistance in Enterococcus faecalis, Dryad, Dataset, https://doi.org/10.5061/dryad.j3tx95x92 There are no restrictions on any new results.

Dryad Digital RepositoryData from: Antibiotic interactions shape shortterm evolution of resistance in Enterococcus faecalis.https://doi.org/10.5061/dryad.j3tx95x92
References

Crossfeeding modulates antibiotic tolerance in bacterial communitiesThe ISME Journal 12:2723–2735.https://doi.org/10.1038/s413960180212z

Antibiotic resistance and its cost: is it possible to reverse resistance?Nature Reviews Microbiology 8:260–271.https://doi.org/10.1038/nrmicro2319

Limited evolutionary conservation of the phenotypic effects of antibiotic resistance mutationsMolecular Biology and Evolution 36:1601–1611.https://doi.org/10.1093/molbev/msz109

Isolated cell behavior drives the evolution of antibiotic resistanceMolecular Systems Biology 11:822.https://doi.org/10.15252/msb.20145888

Alternative evolutionary paths to bacterial antibiotic resistance cause distinct collateral effectsMolecular Biology and Evolution 34:2229–2244.https://doi.org/10.1093/molbev/msx158

Antibiotic cycling and antibiotic mixing: which one best mitigates antibiotic resistance?Molecular Biology and Evolution 34:msw292–817.https://doi.org/10.1093/molbev/msw292

Epistasis between antibiotic resistance mutations drives the evolution of extensively drugresistant tuberculosisEvolution, Medicine, and Public Health 2013:65–74.https://doi.org/10.1093/emph/eot003

Origin and proliferation of multipledrug resistance in bacterial pathogensMicrobiology and Molecular Biology Reviews 79:101–116.https://doi.org/10.1128/MMBR.0003914

Origins and evolution of antibiotic resistanceMicrobiology and Molecular Biology Reviews 74:417–433.https://doi.org/10.1128/MMBR.0001610

The price equation and evolutionary epidemiologyPhilosophical Transactions of the Royal Society B: Biological Sciences 375:20190357.https://doi.org/10.1098/rstb.2019.0357

Insights from price's equation into evolutionaryDisease Evolution: Models, Concepts, and Data Analyses 71:23.https://doi.org/10.1090/dimacs/071/02

Tuning spatial profiles of selection pressure to modulate the evolution of drug resistancePhysical Review Letters 120:238102.https://doi.org/10.1103/PhysRevLett.120.238102

Empirical fitness landscapes and the predictability of evolutionNature Reviews Genetics 15:480–490.https://doi.org/10.1038/nrg3744

Fitness landscapes emerging from pharmacodynamic functions in the evolution of multidrug resistanceJournal of Evolutionary Biology 27:840–853.https://doi.org/10.1111/jeb.12355

Continuous stability and evolutionary convergenceJournal of Theoretical Biology 185:333–343.https://doi.org/10.1006/jtbi.1996.0312

Community interactions and spatial structure shape selection on antibiotic resistant lineagesPLOS Computational Biology 14:e1006179.https://doi.org/10.1371/journal.pcbi.1006179

George price's contributions to evolutionary geneticsJournal of Theoretical Biology 175:373–388.https://doi.org/10.1006/jtbi.1995.0148

Cooperation, competition and antibiotic resistance in bacterial coloniesThe ISME Journal 12:1582–1593.https://doi.org/10.1038/s4139601800904

The search for synergy: a critical review from a response surface perspectivePharmacological Reviews 47:331–385.

Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance developmentScience Translational Medicine 5:204ra132.https://doi.org/10.1126/scitranslmed.3006609

The price equation, gradient dynamics, and continuous trait game theoryThe American Naturalist 191:146–153.https://doi.org/10.1086/694891

Fifty years of the price equationPhilosophical Transactions of the Royal Society B: Biological Sciences 375:20190350.https://doi.org/10.1098/rstb.2019.0350

Antibacterial resistance worldwide: causes, challenges and responsesNature Medicine 10:S122–S129.https://doi.org/10.1038/nm1145

The population dynamics of antimicrobial chemotherapyAntimicrobial Agents and Chemotherapy 41:363–373.https://doi.org/10.1128/AAC.41.2.363

The problem of synergism and antagonism of combined drugsArzneimittelForschung 3:285–290.

Antibiotics as a selective driver for conjugation dynamicsNature Microbiology 1:16044.https://doi.org/10.1038/nmicrobiol.2016.44

Persistence and reversal of plasmidmediated antibiotic resistanceNature Communications 8:1689.https://doi.org/10.1038/s41467017015321

Using selection by nonantibiotic stressors to sensitize Bacteria to antibioticsMolecular Biology and Evolution 37:1394–1406.https://doi.org/10.1093/molbev/msz303

Bacterial temporal dynamics enable optimal design of antibiotic treatmentPLOS Computational Biology 11:e1004201.https://doi.org/10.1371/journal.pcbi.1004201

Collective antibiotic tolerance: mechanisms, dynamics and interventionNature Chemical Biology 11:182–188.https://doi.org/10.1038/nchembio.1754

Prediction of resistance development against drug combinations by collateral responses to component drugsScience Translational Medicine 6:262ra156.https://doi.org/10.1126/scitranslmed.3009940

Steering evolution with sequential therapy to prevent the emergence of bacterial antibiotic resistancePLOS Computational Biology 11:e1004493.https://doi.org/10.1371/journal.pcbi.1004493

Competition along trajectories governs adaptation rates towards antimicrobial resistanceNature Ecology & Evolution 1:0007.https://doi.org/10.1038/s415590160007

BookA Biologist's Guide to Mathematical Modeling in Ecology and EvolutionPrinceton University Press.https://doi.org/10.1111/j.14429993.2007.01856.x

Collateral sensitivity of antibioticresistant microbesTrends in Microbiology 23:401–407.https://doi.org/10.1016/j.tim.2015.02.009

BookThe Antibiotic Era: Reform, Resistance, and the Pursuit of a Rational TherapeuticsJohns Hopkins University Press.https://doi.org/10.3201/eid2106.150212

Extension of covariance selection mathematicsAnnals of Human Genetics 35:485–490.https://doi.org/10.1111/j.14691809.1957.tb01874.x

Collateral resistance and sensitivity modulate evolution of HighLevel resistance to drug combination treatment in Staphylococcus aureusMolecular Biology and Evolution 32:1175–1185.https://doi.org/10.1093/molbev/msv006

Additivity of inhibitory effects in multidrug combinationsNature Microbiology 3:1339–1345.https://doi.org/10.1038/s4156401802521

BookEvolution and the Theory of GamesCambridge University Press.https://doi.org/10.1017/CBO9780511806292

The inoculum effect and bandpass bacterial response to periodic antibiotic treatmentMolecular Systems Biology 8:617.https://doi.org/10.1038/msb.2012.49

Enhanced identification of synergistic and antagonistic emergent interactions among three or more drugsJournal of the Royal Society Interface 13:20160332.https://doi.org/10.1098/rsif.2016.0332

Measuring higherorder drug interactions: a review of recent approachesCurrent Opinion in Systems Biology 4:16–23.https://doi.org/10.1016/j.coisb.2017.05.015

General form for interaction measures and framework for deriving HigherOrder emergent effectsFrontiers in Ecology and Evolution 6:166.https://doi.org/10.3389/fevo.2018.00166

Optimal drug synergy in antimicrobial treatmentsPLOS Computational Biology 6:e1000796.https://doi.org/10.1371/journal.pcbi.1000796

Issues of terminology, gradient dynamics and the ease of sympatric speciation in adaptive dynamicsJournal of Evolutionary Biology 18:1214–1219.https://doi.org/10.1111/j.14209101.2005.00953.x

Clinical management of resistance evolution in a bacterial infection: a case studyEvolution, Medicine, and Public Health 2015:281–288.https://doi.org/10.1093/emph/eov025
Article and author information
Author details
Funding
National Institutes of Health (1R35GM124875)
 Kevin B Wood
National Science Foundation (1553028)
 Kevin B Wood
Fundação LusoAmericana para o Desenvolvimento (274/2016)
 Erida Gjini
Calouste Gulbenkian Foundation
 Erida Gjini
FCT (UIDB/04621/2020)
 Erida Gjini
FCT (UIDP/04621/2020)
 Erida Gjini
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Acknowledgements
This work was supported by Fundação LusoAmericana para o Desenvolvimento (FLAD/NSF grant274/2016 to EG) and Instituto Gulbenkian de Ciência, the National Science Foundation (NSF No. 1553028 to KW), and the National Institutes of Health (NIH No. 1R35GM124875 to KW). The Center for Stochastic and Computational Mathematics is supported by FCT via UIDB/04621/2020 and UIDP/04621/2020.
Version history
 Received: November 13, 2020
 Accepted: July 8, 2021
 Accepted Manuscript published: July 22, 2021 (version 1)
 Accepted Manuscript updated: July 26, 2021 (version 2)
 Version of Record published: August 3, 2021 (version 3)
Copyright
© 2021, Gjini and Wood
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics

 2,199
 views

 267
 downloads

 29
 citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading

 Evolutionary Biology
 Genetics and Genomics
The evolutionary origins of Bilateria remain enigmatic. One of the more enduring proposals highlights similarities between a cnidarianlike planula larva and simple acoellike flatworms. This idea is based in part on the view of the Xenacoelomorpha as an outgroup to all other bilaterians which are themselves designated the Nephrozoa (protostomes and deuterostomes). Genome data can provide important comparative data and help to understand the evolution and biology of enigmatic species better. Here we assemble and analyse the genome of the simple, marine xenacoelomorph Xenoturbella bocki, a key species for our understanding of early bilaterian evolution. Our highly contiguous genome assembly of X. bocki has a size of ~111 Mbp in 18 chromosome like scaffolds, with repeat content and intron, exon and intergenic space comparable to other bilaterian invertebrates. We find X. bocki to have a similar number of genes to other bilaterians and to have retained ancestral metazoan synteny. Key bilaterian signalling pathways are also largely complete and most bilaterian miRNAs are present. Overall, we conclude that X. bocki has a complex genome typical of bilaterians, which does not reflect the apparent simplicity of its body plan that has been so important to proposals that the Xenacoelomorpha are the simple sister group of the rest of the Bilateria.

 Evolutionary Biology
 Microbiology and Infectious Disease
HERVK(HML2), the youngest clade of human endogenous retroviruses (HERVs), includes many intact or nearly intact proviruses, but no replication competent HML2 proviruses have been identified in humans. HML2related proviruses are present in other primates, including rhesus macaques, but the extent and timing of HML2 activity in macaques remains unclear. We have identified 145 HML2like proviruses in rhesus macaques, including a clade of young, rhesusspecific insertions. Age estimates, intact ORFs, and insertional polymorphism of these insertions are consistent with recent or ongoing infectious activity in macaques. 106 of the proviruses form a clade characterized by an ~750 bp sequence between env and the 3' LTR, derived from an ancient recombination with a HERVK(HML8)related virus. This clade is found in Old World monkeys (OWM), but not great apes, suggesting it originated after the ape/OWM split. We identified similar proviruses in whitecheeked gibbons; the gibbon insertions cluster within the OWM recombinant clade, suggesting interspecies transmission from OWM to gibbons. The LTRs of the youngest proviruses have deletions in U3, which disrupt the Rec Response Element (RcRE), required for nuclear export of unspliced viral RNA. We show that the HML8 derived region functions as a Recindependent constitutive transport element (CTE), indicating the ancestral RecRcRE export system was replaced by a CTE mechanism.